Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 18-27

  Rosén, Anders ^a   Bergh, Ann Charlotte ^a   Gogolák, Peter ^b,f   Evaldsson, Chamilly ^a   Myhrinder, Anna Lanemo ^a   Hellqvist, Eva ^a   Rasul, Abu ^b   Björkholm, Magnus ^c   Jansson, Mattias ^d   Mansouri, Larry ^d   Liu, Anquan ^b,c   Teh, Bin Tean ^e   Rosenquist, Richard ^d   Klein, Eva ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cell of origin; Chronic lymphocytic leukemia; Human b1 cells; Leukemogenesis; Lymphoblastoid cell line; Self renewing hematopoietic stem cells

Indexed keywords

CD20 ANTIGEN; CD27 ANTIGEN; CD5 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN M ANTIBODY; LATENT MEMBRANE PROTEIN 1; LEUKOSIALIN; MICRORNA 15A; MICRORNA 16;

AGED; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL CLONING; CELL RENEWAL; CELL SURFACE; CELL TRANSFORMATION; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR SUBFAMILY A MEMBER 4 GENE; LIM HOMEOBOX 2 GENE; LYMPHOBLASTOID CELL LINE; MALE; PARD3 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866491283     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.18400     Document Type: Article

References (64)

1. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625-38; PMID:11733577; http://dx.doi.org/10.1084/jem.194.11.1625.
2. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-47; PMID:11733578; http://dx.doi.org/10.1084/jem.194.11.1639.
3. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99:4087-93; PMID:12010811; http://dx.doi.org/10.1182/blood.V99.11.4087.
4. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011; 208:67-80; PMID: 21220451; http://dx.doi.org/10.1084/jem.20101499.
5. Kikushige Y, Ishikawa F, Miyamoto T, Shima T, Urata S, Yoshimoto G, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20:246-59; PMID:21840488; http://dx.doi.org/10.1016/j.ccr.2011.06.029.
6. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371:1017-29; PMID: 18358929; http://dx.doi.org/10.1016/S0140-6736(08)60456-0.
7. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 1997; 89:2833-41; PMID:9108402.
8. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111:3838-48; PMID:18223168; http://dx.doi.org/10.1182/blood-2007-11-125450.
9. Chu CC, Catera R, Hatzi K, Yan XJ, Zhang L, Wang XB, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008; 112:5122-9; PMID:18812466; http://dx.doi.org/10.1182/blood-2008-06-162024.
10. Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008; 14:665-74; PMID: 19009014; http://dx.doi.org/10.2119/2008-00102.
11. Rosén A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia-Implications for cell origin and leukemogenesis. Semin Cancer Biol 2010; 20:400-9; PMID:20863893; http://dx.doi.org/10.1016/j.semcancer.2010.09.004.
12. Takada K, Yamamoto K, Osato T. Analysis of the transformation of human lymphocytes by Epstein-Barr virus. II. Abortive response of leukemic cells to the transforming virus. Intervirology 1980; 13:223-31; PMID:6248483; http://dx.doi.org/10.1159/000149129.
13. Walls EV, Doyle MG, Patel KK, Allday MJ, Catovsky D, Crawford DH. Activation and immortalization of leukaemic B cells by Epstein-Barr virus. Int J Cancer 1989; 44:846-53; PMID:2555307; http://dx.doi.org/10.1002/ijc.2910440517.
14. Avila-Cariño J, Lewin N, Tomita Y, Szeles A, Sandlund A, Mosolits S, et al. B-CLL cells with unusual properties. Int J Cancer 1997; 70:1-8; PMID: 8985083; http://dx.doi.org/10.1002/(SICI)1097-0215(19970106)70:1,1::AID-IJC1.3.0. CO;2-1.
15. Wendel-Hansen V, Sällström J, De Campos-Lima PO, Kjellström G, Sandlund A, Siegbahn A, et al. Epstein-Barr virus (EBV) can immortalize B-cll cells activated by cytokines. Leukemia 1994; 8:476-84; PMID: 8127151.
16. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R. EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 2008; 45:3133-41; PMID:18430472; http://dx.doi.org/10.1016/j.molimm.2008.03.002.
17. Bandobashi K, Liu A, Nagy N, Kis LL, Nishikawa J, Bjorkholm M, et al. EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells. Virus Genes 2005; 30:323-30; PMID:15830149; http://dx.doi.org/10.1007/s11262-004-6774-z.
18. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111:1524-33; PMID:17959859; http://dx.doi.org/10.1182/blood-2007-07-099564.
19. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117:1781-91; PMID:21148333; http://dx.doi.org/10.1182/blood-2010-07-155663.
20. Stein H, Schwarting R, Niedobitek G, Dallenbach F. Cluster report: CD70. Oxford, UK: Oxford University Press; 1989.
21. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85:3556-65; PMID: 7540066.
22. Yamada S, Shinozaki K, Agematsu K. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol 2002; 130:424-30; PMID:12452832; http://dx.doi.org/10.1046/j.1365-2249.2002.02012.x.
23. Tomita Y, Avila-Carino J, Yamamoto K, Mellstedt H, Klein E. Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes. Immunol Lett 1998; 60:73-9; PMID:9580478; http://dx.doi.org/10.1016/S0165-2478(97)00142-9.
24. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118:3603-12; PMID:21803855; http://dx.doi.org/10.1182/blood-2011-05-352492.
25. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NFkappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117:563-74; PMID:20940416; http://dx.doi.org/10.1182/blood-2010-05-284984.
26. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9:405-11; PMID:9768760; http://dx.doi.org/10.1016/S1074-7613(00)80623-8.
27. Kearney JF. Innate-like B cells. Springer Semin Immunopathol 2005; 26:377-83; PMID:15645296; http://dx.doi.org/10.1007/s00281-004-0184-0.
28. Youinou P, Renaudineau Y. CD5 expression in B cells from patients with systemic lupus erythematosus. Crit Rev Immunol 2011; 31:31-42; PMID:21395509.
29. Klein E, Nagy N. Restricted expression of EBV encoded proteins in in vitro infected CLL cells. Semin Cancer Biol 2010; 20:410-5; PMID:21034831; http://dx.doi.org/10.1016/j.semcancer.2010.10.013.
30. Kaplan D, Smith D, Meyerson H, Pecora N, Lewandowska K. CD5 expression by B lymphocytes and its regulation upon Epstein-Barr virus transformation. Proc Natl Acad Sci USA 2001; 98:13850-3; PMID:11707593; http://dx.doi.org/10.1073/pnas.241509398.
31. Wendel-Hansen V, Rosén A, Klein G. EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int J Cancer 1987; 39:404-8; PMID:3546163; http://dx.doi.org/10.1002/ijc.2910390322.
32. Dahl L, Richter K, Hägglund AC, Carlsson L. Lhx2 expression promotes self-renewal of a distinct multipotential hematopoietic progenitor cell in embryonic stem cell-derived embryoid bodies. PLoS ONE 2008; 3:e2025; PMID:18431502; http://dx.doi.org/10.1371/journal.pone.0002025.
33. Xu Y, Baldassare M, Fisher P, Rathbun G, Oltz EM, Yancopoulos GD, et al. LH-2: a LIM/homeodomain gene expressed in developing lymphocytes and neural cells. Proc Natl Acad Sci USA 1993; 90:227-31; PMID:7678338; http://dx.doi.org/10.1073/pnas.90.1.227.
34. Wu HK, Heng HH, Siderovski DP, Dong WF, Okuno Y, Shi XM, et al. Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous leukaemia and located on 9q33-34.1. Oncogene 1996; 12:1205-12; PMID:8649822.
35. Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, Duff D, et al. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 2006; 20:1855-62; PMID:16900213; http://dx.doi.org/10.1038/sj.leu.2404345.
36. Dono M, Burgio VL, Colombo M, Sciacchitano S, Reverberi D, Tarantino V, et al. CD5+ B cells with the features of subepithelial B cells found in human tonsils. Eur J Immunol 2007; 37:2138-47; PMID:17615580; http://dx.doi.org/10.1002/eji.200636887.
37. Barrow AD, Trowsdale J. The extended human leukocyte receptor complex: diverse ways of modulating immune responses. Immunol Rev 2008; 224:98-123; PMID:18759923; http://dx.doi.org/10.1111/j.1600-065X.2008.00653.x.
38. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 2009; 206:1603-14; PMID: 19564354; http://dx.doi.org/10.1084/jem.20090547.
39. Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 2008; 111:1625-33; PMID:18006695; http://dx.doi.org/10.1182/blood-2007-08-110130.
40. Woessner S, Florensa L, Besses C, Vila RM, Galles C, Palou L, et al. Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies. Leuk Res 1992; 16:505-10; PMID:1378160; http://dx.doi.org/10.1016/0145-2126(92)90177-9.
41. Wroblewski JM, Copple A, Batson LP, Landers CD, Yannelli JR. Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods 2002; 264:19-28; PMID:12191505; http://dx.doi.org/10.1016/S0022-1759(01)00565-8.
42. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998; 392:505-9; PMID:9548256; http://dx.doi.org/10.1038/33169.
43. Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20:286-95; PMID:16341037; http://dx.doi.org/10.1038/sj.leu.2404061.
44. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010; 207: 2689-701; PMID:21078886; http://dx.doi.org/10.1084/jem.20101111.
45. Seiffert M, Schulz A, Ohl S, Dohner H, Stilgenbauer S, Lichter P. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010; 116:4223-30; PMID:20660791; http://dx.doi.org/10.1182/blood-2010-05-284505.
46. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010; 115:3907-15; PMID:20110421; http://dx.doi.org/10.1182/blood-2009-09-244251.
47. Brown S, Heinisch I, Ross E, Shaw K, Buckley CD, Savill J. Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 2002; 418:200-3; PMID:12110892; http://dx.doi.org/10.1038/nature00811.
48. Lenz LL. CD5 sweetens lymphocyte responses. Proc Natl Acad Sci USA 2009; 106:1303-4; PMID: 19174525; http://dx.doi.org/10.1073/pnas.0812579106.
49. Vera J, Fenutria R, Canadas O, Figueras M, Mota R, Sarrias MR, et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci USA 2009; 106:1506-11; PMID: 19141631; http://dx.doi.org/10.1073/pnas.0805846106.
50. Montecino-Rodriguez E, Leathers H, Dorshkind K. Identification of a B-1 B cell-specified progenitor. Nat Immunol 2006; 7:293-301; PMID:16429139; http://dx.doi.org/10.1038/ni1301.
51. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110:3352-9; PMID:17684154; http://dx.doi.org/10.1182/blood-2007-04-083832.
52. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res 2010; 70:2158-64; PMID:20215515; http://dx.doi.org/10.1158/0008-5472.CAN-09-3458.
53. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799.
54. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 2010; 20:377-83; PMID:21029776; http://dx.doi.org/10.1016/j.semcancer.2010.10.012.
55. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17:28-40; PMID: 20060366; http://dx.doi.org/10.1016/j.ccr.2009.11.019.
56. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, et al. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood 2010; 115:3916-22; PMID:20071661; http://dx.doi.org/10.1182/blood-2009-10-249367.
57. Fialkow PJ, Najfeld V, Reddy AL, Singer J, Steinmann L. Chronic lymphocytic leukaemia: Clonal origin in a committed B-lymphocyte progenitor. Lancet 1978; 2:444-6; PMID:79806; http://dx.doi.org/10.1016/S0140-6736(78)91444-7.
58. Karande A, Fialkow PJ, Nilsson K, Povey S, Klein G, Najfeld V, et al. Establishment of a lymphoid cell line from leukemic cells of a patient with chronic lymphocytic leukemia. Int J Cancer 1980; 26:551-6; PMID:6263808; http://dx.doi.org/10.1002/ijc.2910260505.
59. Najfeld V, Fialkow PJ, Karande A, Nilsson K, Klein G, Penfold G. Chromosome analyses of lymphoid cell lines derived from patients with chronic lymphocytic leukemia. Int J Cancer 1980; 26:543-9; PMID: 7239716; http://dx.doi.org/10.1002/ijc.2910260504.
60. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23:127-36; PMID:10071128; http://dx.doi.org/10.1016/S0145-2126(98)00154-4.
61. Karhu R, Vilpo L, Isola J, Knuutila S, Vilpo J. Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation. Genes Chromosomes Cancer 2002; 34:345-8; PMID:12007196; http://dx.doi.org/10.1002/gcc.10074.
62. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001; 98:9754-9; PMID:11493696; http://dx.doi.org/10.1073/pnas.171209998.
63. Tobin G, Thunberg U, Johnson A, Thörn I, Söderberg O, Hultdin M, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99:2262-4; PMID:11877310; http://dx.doi.org/10.1182/blood.V99.6.2262.
64. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003; 108: 2107-12; PMID:14530200; http://dx.doi.org/10.1161/01.CIR.0000092891.55157.A7www.